Silo Pharma prioritizes 2024 pipeline targeting PTSD, chronic pain, neurology; plans Pre-IND for SPC-15 by Q2

Silo Pharma, Inc.

Lead program SPC-15 (intranasal PTSD prophylactic) Pre-IND submission planned by end of Q2 2024.
SP-26 is a non-opioid, time-release ketamine implant for fibromyalgia, potential first at-home ketamine treatment.
SPC-14 (Alzheimer's) positive animal results; more data expected in 2024; SPU-16 targets MS via homing peptide.
FDA 505(b)(2) pathway to be used for SPC-15, SP-26, and SPC-14 to expedite approval and reduce costs.
Pipeline includes four drugs across three therapeutic areas: mental health, chronic pain, and neurology.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.